Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS6099-TPS6099
Author(s):  
Laura Locati ◽  
Carmela Aves Caballero ◽  
Catherine Fortpied ◽  
Federica Perrone ◽  
Pasquale Quattrone ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Androgen Receptor ◽  
Androgen Deprivation Therapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Androgen Deprivation ◽  
Salivary Gland Cancer ◽  
Efficacy And Safety ◽  
Randomized Phase Ii

scholarly journals A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer

2021 ◽  
Author(s):  
Phillip L. Palmbos ◽  
Stephanie Daignault-Newton ◽  
Scott A. Tomlins ◽  
Neeraj Agarwal ◽  
Przemyslaw Twardowski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Androgen Deprivation ◽  
Randomized Phase Ii ◽  
Hormone Sensitive

A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS5074-TPS5074 ◽  
Author(s):  
Phillip Lee Palmbos ◽  
Felix Yi-Chung Feng ◽  
Scott A. Tomlins ◽  
William Kevin Kelly ◽  
Alicia Katherine Morgans ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Androgen Deprivation ◽  
Randomized Phase Ii ◽  
Hormone Sensitive

scholarly journals Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

2020 ◽  
Vol 10 ◽  
Author(s):  
Julie N. Graff ◽  
Mark N. Stein ◽  
Rishi Surana ◽  
Luai Al Rabadi ◽  
Eric Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Androgen Deprivation ◽  
Incomplete Response

scholarly journals Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

2019 ◽  
Vol 181 (1) ◽  
pp. 88-95 ◽  
Author(s):  
K. Reich ◽  
P. Rich ◽  
C. Maari ◽  
R. Bissonnette ◽  
C. Leonardi ◽  
...  
Keyword(s):  
Phase Ii ◽  
Plaque Psoriasis ◽  
Phase Ii Study ◽  
Efficacy And Safety ◽  
Severe Plaque Psoriasis ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document